Zipalertinib Combination Boosts Survival in First-Line Lung Cancer Trial

The international study tracked 279 patients, revealing that the combination therapy reduced the risk of disease progression or death by 50% compared to chemotherapy alone. Blinded independent reviews recorded a median progression-free survival of 14.5 months for the treatment group, significantly outperforming the 8.5-month benchmark set by the control arm. Benefits remained consistent even among patients with brain metastases, where a hazard ratio of 0.38 was observed.

Professor Daniel Tan of the National Cancer Centre Singapore noted that the regimen also yielded a 65% objective response rate, compared to 40.3% for those receiving only chemotherapy. While Grade 3 or higher adverse events appeared in 87.1% of the combination group—largely due to hematologic factors—researchers reported no new safety signals. The trial, registered as NCT05973773, continues to monitor overall survival as the study matures.